{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:53:44Z","timestamp":1788900824322,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013885","name":"Ministry of Health Malaysia","doi-asserted-by":"publisher","award":["NMRR-20-328-52925"],"award-info":[{"award-number":["NMRR-20-328-52925"]}],"id":[{"id":"10.13039\/501100013885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijid.2026.108788","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:16:44Z","timestamp":1778818604000},"page":"108788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir\/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial)"],"prefix":"10.1016","volume":"169","author":[{"given":"Muhammad Radzi","family":"Abu Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-2103","authenticated-orcid":false,"given":"Nor Asiah","family":"Muhamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Syahireen","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Azri","family":"Mohd Suan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna Nadia","family":"Zulkifli Supramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathya Rao","family":"Jogulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Firdaus","family":"Md Salleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrul Aiman","family":"Soelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzah Athirah","family":"Rosli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatin Norhasny","family":"Leman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Soleha","family":"Mohd Dali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Hasnah","family":"Maamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Fariza","family":"Ngah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Keat","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108788_bib0001","series-title":"Hepatitis C","year":"2025"},{"key":"10.1016\/j.ijid.2026.108788_bib0002","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"key":"10.1016\/j.ijid.2026.108788_bib0003","series-title":"Hepatitis C Fact Sheets","year":"2024"},{"key":"10.1016\/j.ijid.2026.108788_bib0004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/v14010096","article-title":"Are there still difficult-to-treat patients with chronic Hepatitis C in the era of direct-acting antivirals?","volume":"14","author":"Pabjan","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2026.108788_bib0006","article-title":"Embedding viral hepatitis into primary healthcare: results of a strategic landscape analysis in Vietnam and the Philippines","volume":"44","author":"Holt","year":"2024","journal-title":"Lancet Reg Health - West Pac"},{"key":"10.1016\/j.ijid.2026.108788_bib0007","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S2468-1253(24)00121-3","article-title":"Urgent action needed to achieve viral hepatitis elimination","volume":"9","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12889-022-12786-w","article-title":"Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders","volume":"22","author":"Chan","year":"2022","journal-title":"BMC Pub Health"},{"key":"10.1016\/j.ijid.2026.108788_bib0009","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: conquering mount improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ijid.2026.108788_bib0010","doi-asserted-by":"crossref","first-page":"e1496","DOI":"10.1016\/S2214-109X(21)00357-0","article-title":"Ravidasvir: equitable access through an alternative drug development pathway","volume":"9","author":"Cheong","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijid.2026.108788_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2017.09.006","article-title":"Effectiveness of ravidasvir plus sofosbuvir in interferon-na\u00efve and treated patients with chronic hepatitis C genotype-4","volume":"68","author":"Esmat","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2468-1253(21)00031-5","article-title":"Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2\/3 trial","volume":"6","author":"Andrieux-Meyer","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0013","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.14428","article-title":"Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt","volume":"47","author":"Omar","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.108788_bib0014","article-title":"SVR12 rates higher than 99% after sofosbuvir\/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: a real world experience","volume":"14","author":"Mangia","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.ijid.2026.108788_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 weeks in patients with Hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0016","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","article-title":"Shortening the duration of therapy for chronic hepatitis C infection","volume":"2","author":"Emmanuel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108788_bib0018","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81801","article-title":"Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study","volume":"12","author":"Flower","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ijid.2026.108788_bib0019","article-title":"Hepatitis C virus (HCV) infection in Malaysia: findings from a nationwide cross-sectional study","volume":"36","author":"Muhammad","year":"2023","journal-title":"Lancet Reg Health - West Pac"},{"key":"10.1016\/j.ijid.2026.108788_bib0020","series-title":"National Strategic Plan for Hepatitis B and C 2019 - 2023","author":"Abu Hassan","year":"2019"},{"key":"10.1016\/j.ijid.2026.108788_bib0021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2468-1253(20)30365-4","article-title":"Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework","volume":"6","author":"Akiyama","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108788_bib0022","unstructured":"Urbaniak G.C., Plous S. Research Randomizer 2013."},{"key":"10.1016\/j.ijid.2026.108788_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24612-9","article-title":"Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection","volume":"12","author":"Suan","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108788_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285725","article-title":"Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-na\u00efve non-cirrhotic patients with chronic hepatitis C virus infection: study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)","volume":"18","author":"Awasthi","year":"2023","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijid.2026.108788_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s13063-020-04350-x","article-title":"The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam","volume":"21","author":"McCabe","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ijid.2026.108788_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108788_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001708","article-title":"Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately","volume":"7","author":"Khan","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.ijid.2026.108788_bib0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","article-title":"The proportion of missing data should not be used to guide decisions on multiple imputation","volume":"110","author":"Madley-Dowd","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijid.2026.108788_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2019.00033","article-title":"Efficacy and safety of all-oral, 12-week Ravidasvir plus Ritonavir-boosted Danoprevir and Ribavirin in treatment-na\u00efve noncirrhotic HCV genotype 1 patients: results from a phase 2\/3 clinical trial in China","volume":"7","author":"Xu","year":"2019","journal-title":"J Clin Transl Hepatol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:25:10Z","timestamp":1785882310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226004236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"alternative-id":["S1201971226004236"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108788","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir\/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108788"}}